EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases | Zendy

Kai Dong | Zendy; Wenhua Liang | Zendy; Shen Zhao | Zendy; Minzhang Guo | Zendy; Qihua He | Zendy; Caichen Li | Zendy; Haiqing Song | Zendy; Jianxing He | Zendy; Xiaojun Xia | Zendy

Open Access

EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases

Author(s) -

Kai Dong,

Wenhua Liang,

Shen Zhao,

Minzhang Guo,

Qihua He,

Caichen Li,

Haiqing Song,

Jianxing He,

Xiaojun Xia

Publication year - 2019

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2019.06.12

Subject(s) - medicine , brain metastasis , oncology , hazard ratio , subgroup analysis , epidermal growth factor receptor , lung cancer , erlotinib , population , proportional hazards model , tyrosine kinase inhibitor , meta analysis , cancer , metastasis , confidence interval , environmental health

It has been confirmed that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the treatment of brain metastasis (BM) in EGFR mutated NSCLC patients. However, whether the combination of EGFR-TKIs and brain RT is better than EGFR-TKIs alone remains unclear. We aim to compare the outcomes of adding brain RT to EGFR-TKIs and to screen for the beneficial population by a meta-analysis of currently available data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research